Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1997 Aug;226(2):198–206. doi: 10.1097/00000658-199708000-00012

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.

M K Wallack 1, M Sivanandham 1, K Ditaranto 1, P Shaw 1, C M Balch 1, M M Urist 1, K I Bland 1, D Murray 1, W A Robinson 1, L Flaherty 1, J M Richards 1, L Rosen 1, A A Bartolucci 1
PMCID: PMC1190955  PMID: 9296514

Abstract

OBJECTIVE: The efficacy of vaccinia melanoma oncolysate (VMO) vaccine to increase overall survival and disease-free survival of patients with surgically resected International Union Against Cancer (UICC) stage II melanoma was studied in a phase III, randomized, multi-institutional trial. SUMMARY BACKGROUND DATA: Phase I and II trials with VMO showed minimal toxicity and clinical efficacy in patients with melanoma. In a recently completed phase III VMO trial, the first interim analysis performed in April 1994 showed an increasing trend in the survival of patients treated with VMO. The second interim analysis was performed in April 1995. METHODS: Patients with surgically resected stage II (UICC) melanoma were treated with VMO (N = 104) or placebo vaccinia vaccine virus (V) (N = 113) once a week for 13 weeks and then once every 2 weeks for a total of 12 months. Patients' clinical data were collected as of May 1995 and analyzed for survival. RESULTS: In this second interim analysis, the mean follow-up time is 42.28 months. No survival difference was observed between VMO and V treatments. However, in a retrospective subset analysis, a subset of males between the ages of 44 and 57 years and having one to five positive nodes (at 2-, 3-, and 5-year intervals, 13.6%, 15.9%, and 20.3% difference insurvival in favor of VMO [N = 20] when compared to V [N = 18] [p = 0.037]) and another subset of patients with clinical stage I (at 3- and 5-year intervals, 30% and 7% difference in survival in favor of VMO [N = 20] when compared to V [N = 23], [p = 0.05]) showed significant survival advantage with VMO. CONCLUSIONS: Although VMO vaccine therapy in surgical adjuvant setting did not produce a significant survival benefit to all patients with melanoma, patients from the above two subsets had significant survival benefit.

Full text

PDF
198

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arroyo P. J., Bash J. A., Wallack M. K. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol Immunother. 1990;31(5):305–311. doi: 10.1007/BF01740939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bystryn J. C., Oratz R., Roses D., Harris M., Henn M., Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer. 1992 Mar 1;69(5):1157–1164. doi: 10.1002/cncr.2820690516. [DOI] [PubMed] [Google Scholar]
  3. Hersey P., Edwards A., Coates A., Shaw H., McCarthy W., Milton G. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol Immunother. 1987;25(3):257–265. doi: 10.1007/BF00199156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
  5. Lindenmann J., Klein P. A. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med. 1967 Jul 1;126(1):93–108. doi: 10.1084/jem.126.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Livingston P. O., Wong G. Y., Adluri S., Tao Y., Padavan M., Parente R., Hanlon C., Calves M. J., Helling F., Ritter G. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994 May;12(5):1036–1044. doi: 10.1200/JCO.1994.12.5.1036. [DOI] [PubMed] [Google Scholar]
  7. Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau H. Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988 Oct 15;48(20):5883–5893. [PubMed] [Google Scholar]
  8. Mittelman A., Chen Z. J., Kageshita T., Yang H., Yamada M., Baskind P., Goldberg N., Puccio C., Ahmed T., Arlin Z. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest. 1990 Dec;86(6):2136–2144. doi: 10.1172/JCI114952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Morton D. L., Foshag L. J., Nizze J. A., Gupta R. K., Famatiga E., Hoon D. S., Irie R. F. Active specific immunotherapy in malignant melanoma. Semin Surg Oncol. 1989;5(6):420–425. doi: 10.1002/ssu.2980050608. [DOI] [PubMed] [Google Scholar]
  10. Roenigk H. H., Jr, Deodhar S., St Jacques R., Burdick K. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol. 1974 May;109(5):668–673. [PubMed] [Google Scholar]
  11. Sivanandham M., Scoggin S. D., Tanaka N., Wallack M. K. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother. 1994 Apr;38(4):259–264. doi: 10.1007/BF01533517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tanaka N., Sivanandham M., Wallack M. K. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma. J Immunother Emphasis Tumor Immunol. 1994 Nov;16(4):283–293. doi: 10.1097/00002371-199411000-00006. [DOI] [PubMed] [Google Scholar]
  13. Wallack M. K., Bash J. A., Leftheriotis E., Seigler H., Bland K., Wanebo H., Balch C., Bartolucci A. A. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg. 1987 Dec;122(12):1460–1463. doi: 10.1001/archsurg.1987.01400240108020. [DOI] [PubMed] [Google Scholar]
  14. Wallack M. K., McNally K. R., Leftheriotis E., Seigler H., Balch C., Wanebo H., Bartolucci A. A., Bash J. A. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer. 1986 Feb 1;57(3):649–655. doi: 10.1002/1097-0142(19860201)57:3<649::aid-cncr2820570342>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  15. Wallack M. K., Meyer M., Bourgoin A., Doré J. F., Leftheriotis E., Carcagne J., Koprowski H. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Response Mod. 1983;2(6):586–596. [PubMed] [Google Scholar]
  16. Wallack M. K., Sivanandham M., Balch C. M., Urist M. M., Bland K. I., Murray D., Robinson W. A., Flaherty L. E., Richards J. M., Bartolucci A. A. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer. 1995 Jan 1;75(1):34–42. doi: 10.1002/1097-0142(19950101)75:1<34::aid-cncr2820750108>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  17. Wallack M. K., Sivanandham M., Whooley B., Ditaranto K., Bartolucci A. A. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial. Ann Surg Oncol. 1996 Mar;3(2):110–117. doi: 10.1007/BF02305788. [DOI] [PubMed] [Google Scholar]
  18. Wallack M. K., Steplewski Z., Koprowski H., Rosato E., George J., Hulihan B., Johnson J. A new approach in specific, active immunotherapy. Cancer. 1977 Feb;39(2):560–564. doi: 10.1002/1097-0142(197702)39:2<560::aid-cncr2820390227>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES